Bleeding Disorders Treatment Market Report 2026

The bleeding disorders treatment market size has grown strongly in recent years. It will grow from $18.45 billion in 2025 to $20.14 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to increasing diagnosis of bleeding disorders, availability of factor replacement therapies, expansion of specialty treatment centers, growth in hospital-based care, improved patient survival rates.

The bleeding disorders treatment market size is expected to see strong growth in the next few years. It will grow to $27.99 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing development of novel therapeutics, rising adoption of personalized medicine, expansion of gene and biologic therapies, growing investment in rare disease research, increased access to specialty healthcare services. Major trends in the forecast period include development of targeted clotting therapies, growing adoption of prophylactic treatment approaches, expansion of personalized treatment regimens, rising focus on long-term disease management, increased use of combination drug therapies.

The rise in the number of diagnosed hemophilia patients is expected to drive the growth of the bleeding disorders treatment market in the coming years. Hemophilia is a genetic bleeding disorder in which the blood does not clot properly. Treating hemophilia involves replacement therapy, where the missing or deficient clotting factors are supplemented using human plasma concentrates or recombinant forms of clotting factors VIII or IX. For example, in October 2025, the World Federation of Hemophilia, a Canada-based international non-profit organization, reported a 6% increase in the global identification of individuals with hemophilia, a 6% increase in those diagnosed with VWD, and a 9% increase in the detection of other inherited bleeding disorders. Consequently, the growing number of diagnosed hemophilia patients is fueling the expansion of the bleeding disorders treatment market.

Key companies in the bleeding disorder treatment market are focusing on developing on-demand therapies to manage bleeding episodes and perioperative care during surgeries to cater to a larger patient base, boost sales, and enhance revenue. On-demand treatment plays a vital role in managing bleeding disorders, enabling patients to respond quickly to bleeding episodes and ensuring safe surgical care. Innovations in clotting factor therapies and treatment approaches continue to enhance the quality of life for individuals with bleeding disorders, allowing them to live more active and fulfilling lives. For instance, in February 2023, Sanofi, a France-based healthcare and pharmaceutical company, and Swedish Orphan Biovitrum AB (Sobi), a Sweden-based biopharmaceutical company, collaborated to develop the first-in-class, high-sustained factor VIII replacement therapy ALTUVIIIO, which received U.S. FDA approval. Hemophilia ALTUVIIIO is the first therapy of its kind that, when administered once weekly, maintains factor activity levels above 40% - normal to near-normal for most of the week - significantly reducing bleeding compared to previous factor VIII prophylaxis.

In June 2023, Baudax Bio, Inc., a US-based biopharmaceutical company, acquired TeraImmune, Inc. for an undisclosed sum. Through this acquisition, Baudax Bio plans to utilize TeraImmune’s T-cell Receptor (TCR)-Treg cell therapy platform, particularly the TeraImmune-168 (TI-168) therapy for Hemophilia A patients with inhibitors, to advance clinical development and address a critical unmet need in bleeding disorders. TeraImmune, Inc. is a US-based biotechnology company specializing in developing cell therapies for immune-mediated diseases.

Major companies operating in the bleeding disorders treatment market are AbbVie Inc., Bayer AG, Novo Nordisk A/S, Pfizer Inc., Biogen Inc., CSL Behring Company, Grifols SA, Octapharma AG, BDI Pharma Inc., Ferring Pharmaceuticals Ltd., Xenetic Biosciences Inc., Sanofi SA, Alnylam Pharmaceuticals Inc., Novartis AG, Shire plc, F. Hoffmann-La Roche AG, Sanofi Corporation, Takeda Pharmaceutical Company Limited, Kedrion S.p.A, Biotest AG, LFB S.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., HEMA Biologics LLC, ADMA Biologics Inc., Grifols Biologicals Inc., Octapharma Plasma Inc., Kedrion Biopharma Inc., BPL Plasma Inc., BioLife Plasma Services, CSL Plasma Ltd., Grifols Shared Services North America Inc., Octapharma USA Inc., Shire US Inc., Pfizer Canada Inc., Grifols Canada Ltd., Octapharma Canada Inc.

North America was the largest region in the bleeding disorders treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bleeding disorders treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bleeding disorders treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the bleeding disorders treatment market by increasing costs of imported biologics, plasma-derived products, pharmaceutical ingredients, and advanced drug delivery systems. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported therapies, while emerging markets face higher treatment costs and limited access. These tariffs are increasing treatment expenses and impacting affordability. However, they are also encouraging domestic drug manufacturing, regional production of biologics, and investment in localized pharmaceutical supply chains.

The bleeding disorders treatment market research report is one of a series of new reports that provides bleeding disorders treatment market statistics, including bleeding disorders treatment industry global market size, regional shares, competitors with a bleeding disorders treatment market share, detailed bleeding disorders treatment market segments, market trends and opportunities, and any further data you may need to thrive in the bleeding disorders treatment industry. This bleeding disorders treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bleeding disorders treatment involves medical therapies and interventions designed to manage and control conditions that affect the blood’s ability to clot properly. These treatments aim to prevent excessive bleeding, alleviate symptoms, and enhance quality of life.

The primary treatment types for bleeding disorders include desmopressin (DDAVP), hormone replacement therapy, contraceptives, anti-fibrinolytic or clot-stabilizing drugs, fibrin sealants, topical drugs for cuts, and pipeline analysis. Desmopressin (DDAVP) is used to diagnose and treat individuals with mild hemophilia A or von Willebrand disease to control bleeding. The disorders addressed include hemophilia A, hemophilia B, von Willebrand disease, liver disease, and others, with services provided to end users such as hospitals, clinics, specialty clinics, research institutes, and more.

The bleeding disorders treatment market includes revenues earned by entities by recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.